Sustained virologic suppression after 4 weeks of ledipasvir/sofosbuvir in human immunodeficiency virus (HIV)/hepatitis c virus (HCV) co-infection

Joshua P. Havens, Nichole N. Regan, Sara H. Bares

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Unusual or unexpected effect of treatment Background: Short-course hepatitis C (HCV) treatment with direct-acting antivirals (DAA) under 8 weeks in duration has re-sulted in variable efficacy rates in HCV mono-infection. Further, DAA courses under 8 weeks in duration have not been studied in HIV/HCV co-infection. We present a case report of 12-week sustained virologic suppression after treatment interruption of ledipasvir/sofosbuvir at 4 weeks in a patient with HIV/HCV co-infection. Case Report: A 28-year-old male patient diagnosed with well-controlled HIV infection and HCV co-infection (treatment-naïve, genotype 1a, unknown hepatic fibrosis) started a 12-week course of ledipasvir/sofosbuvir (LDV/SOF) for HCV treatment. The patient completed only 4 weeks of LDV/SOF before returning for follow-up 7 weeks after initi-ation. Ledipasvir/sofosbuvir treatment was discontinued. Sustained virologic suppression at 12 weeks was ob-served after completion of a short, 4-week course of LDV/SOF. Conclusions: Compared to currently recommended treatment durations, clinical trials of short-course DAA treatments of less than 8 weeks have not demonstrated successful rates of SVR12. However, in cases of DAA interruption or in-complete treatment, clinicians may choose to assess for SVR12 prior to continuing or restarting the full treatment course.

Original languageEnglish (US)
Article numbere923326
JournalAmerican Journal of Case Reports
Volume21
DOIs
StatePublished - 2020

Keywords

  • Antiviral Agents
  • HIV Infections
  • Hepatitis C

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sustained virologic suppression after 4 weeks of ledipasvir/sofosbuvir in human immunodeficiency virus (HIV)/hepatitis c virus (HCV) co-infection'. Together they form a unique fingerprint.

Cite this